Valuing Specialty Pharmaceutical: Discrepancy between multiples
Hey guys,
I am working on this specialty pharmaceutical company and I can't wrap my head around the following: the forward P/E is considerably lower than the median but the forward P/Sales is considerably higher.
Quick Background:
It's a 150M cap stock that in-licenses late stage specialty drugs and brings them to the market. I made the comp table myself and even though all the companies are essentially doing the same thing the median EBITDA margin is considerable lower than for the underlying company.
Any thoughts? I really appreciate your help! Thanks
Quisquam modi tempore voluptatibus accusantium molestiae molestiae. Sunt excepturi totam suscipit et nam aspernatur.
Tenetur reprehenderit animi consectetur ad et. Quas quo quae qui eum perferendis porro. Hic pariatur rerum voluptatem quia. Repellendus sint dolor et deserunt ipsum nesciunt.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...